Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

Infection and Immunity

Volumn 70, Issue 8, 2002, Pages 4215-4225

  Coler, Rhea N ^a   Skeiky, Yasir A W ^a   Bernards, Karen ^a   Greeson, Kay ^a   Carter, Darrick ^a   Cornellison, Charisa D ^a   Modabber, Farrokh ^a   Campos Neto, Antonio ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ELONGATION INITIATION FACTOR; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPID A DERIVATIVE; PHOSPHORYL LIPID A; PROTOZOON ANTIBODY; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN; RIBI 529; SQUALENE; STRESS INDUCIBLE PROTEIN 1; THIOL SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; ANTIOXIDANTS; CELL WALL SKELETON; CORD FACTORS; DISEASE MODELS, ANIMAL; FEMALE; HEAT-SHOCK PROTEINS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LIPID A; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR CHAPERONES; PEPTIDE INITIATION FACTORS; PEROXIDASES; POLYPROTEINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

EID: 0036073291     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.8.4215-4225.2002     Document Type: Article

References (51)

1. Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants
2. Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism
3. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
4. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
5. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
6. Mechanism and regulation of immunoglobulin isotype switching
7. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis
8. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63
9. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis
10. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy
11. Vaccine for prophylaxis and immunotherapy Brazil
12. Interleukin 10 production correlates with pathology in human Leishmania donovani infections
13. The present and future of vaccination for cutaneous leishmaniasis
14. Vaccination: Past and future role in control
15. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
16. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
17. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response
18. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: Evidence for expansion of distinct helper T cell subsets
19. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis
20. Recombinant interleukin 12 cures mice infected with Leishmania major
21. Immunoprotective Leishmania major synthetic T cell epitopes
22. Helper T-cell subsets in mouse leishmaniasis: Induction, expansion and effector function
23. Regulation of protective immunity against Leishmania major in mice
24. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection
25. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge
26. First generation leishmaniasis vaccines in clinical development: Moving, but what next?
27. Expression cloning of a protective leishmania antigen
28. Effectiveness of leishmanization in the control of cutaneous leishmaniasis
29. Practical progress and new drugs for changing patterns of leishmaniasis
30. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major
31. A leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells
32. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis
33. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase
34. T-cell and cytokine responses in leishmaniasis
35. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis
36. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
37. IL-12 as an adjuvant for cell-mediated immunity
38. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam
39. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis
40. A recombinant leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
41. LeIF: A recombinant leishmania protein that induces an IL-12-mediated Th1 cytokine profile
42. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis
43. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
44. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
45. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response
46. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
47. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions
48. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
49. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
50. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
51. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major